Ascendis Pharma (ASND) Misses Q4 EPS by 40c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR0.55), EUR0.40 worse than the analyst estimate of (EUR0.15). Revenue for the quarter came in at EUR240 million versus the consensus estimate of EUR245.68 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ross Stores, Inc. (ROST) PT Raised to $239 at UBS on Q2 Earnings Beat
• Alibaba (BABA) PT Lowered to $160 at Baird